Schedule 13G ownership disclosure
APIMEDS PHARMACEUTICALS US I
Common stock, par value $0.01 per share · CUSIP: 03771D102
Event date: 2025-12-31
Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.
- Filing-level shares
- Unavailable
- Percent of class
- Unavailable
- Ayrton Capital LLC
Shares: 1,397,021.00 · Class: 9.99%
- Alto Opportunity Master Fund, SPC - Segregated Master Portfolio B
Shares: 1,397,021.00 · Class: 9.99%
- Waqas Khatri
Shares: 1,397,021.00 · Class: 9.99%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0001493152-26-006136
- Form type
- SCHEDULE 13G
- Filer
- Apimeds Pharmaceuticals US, Inc.
- CIK
- CIK 1894525
- Filed
- Feb 11, 2026
- Reporting period
- Dec 31, 2025
- Description
- Schedule 13G beneficial ownership